A multidisciplinary paper sets out a roadmap for using neurofilament light testing in clinical practice
Original source
Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human
Related topics
A multidisciplinary position paper describes how blood neurofilament light (NfL) testing could be brought into routine care, including for amyotrophic lateral sclerosis (ALS). It highlights laboratory standardisation, quality control and patient factors that affect interpretation. The authors call for regulatory qualification and real-world trials before wider clinical use.
Why this matters
For ALS clinicians and researchers, the paper provides implementation guidance for using NfL as a potential marker of neuroaxonal injury, prognosis or disease monitoring. It does not show that NfL testing improves treatment decisions or outcomes for people with ALS, and it does not change treatment now.
Limitations and context
This is a review and position paper, not a new ALS clinical trial. The source does not report a new ALS-specific patient cohort or establish how NfL should be used for individual treatment decisions. The authors say that harmonised procedures, reference materials and pragmatic real-world trials are still needed.